ASCO23 . Avance de Calado en el Tratamiento de Myeloma Múltiple . El Estudio Cartitude-4 Muestra Que CILTA - CEL ( CARVYKTI By Janssen ) Reduce en un 74% el Riesgo de Progresión o Muerte en Adultos con Mieloma Múltiple en Comparación con Tratamientos Estándar .

 

CILTA- CEL Or Standard Care in Lenalidomide-Refractory Multiple Myeloma .

List of authors : 

Jesús San-Miguel, M.D., Ph.D., 

Binod Dhakal, M.D., 

Kwee Yong, Ph.D., 

Andrew Spencer, M.D. .

CONCLUSIONS :

A Single CILTA - Cel Infusion Resulted in a Lower Risk Of Disease Progression Or Death Than Standard Care in Lenalidomide - Refractory Patients With Múltiple Myeloma Who Had Received One To Three Previous Therapies. (Funded by Janssen and Legend Biotech ;

 CARTITUDE-4 ClinicalTrials.gov Number, NCT04181827. Opens in New tab.) .